We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

62 hedge funds and large institutions have $130M invested in Stemline Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,671% more call options, than puts

Call options by funds: $264K | Put options by funds: $7K

46% more capital invested

Capital invested by funds: $88.9M → $130M (+$41.1M)

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

2% more funds holding

Funds holding: 61 → 62 (+1)

Holders
62
Holders Change
+1
Holders Change %
+1.64%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
19
Reduced
15
Closed
8
Calls
$264K
Puts
$7K
Net Calls
+$257K
Net Calls Change
+$431K

Top Buyers

Rank Fund Capital Flow
1
VM
VHCP Management
New York
+$4.12M
2
Goldman Sachs
Goldman Sachs
New York
+$2.67M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.16M
4
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
+$924K
5
BFA
BlackRock Fund Advisors
California
+$801K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$2.12M
2
VAM
Visium Asset Management
New York
-$1.87M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.24M
4
TC
TFS Capital
Pennsylvania
-$932K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$679K
Name Holding Trade Value Shares
Change 		Change in
Stake
SIP
26
Stoneridge Investment Partners
Pennsylvania
$413K +$69.1K +4,790 +25%
CS
27
Credit Suisse
Switzerland
$406K +$343K +23,809 New
DCM
28
Dupont Capital Management
Delaware
$392K -$85.8K -5,950 -21%
CLOS
29
Compagnie Lombard Odier SCmA
Switzerland
$389K – – –
CWG
30
C WorldWide Group
Denmark
$364K – – –
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$364K +$1.31K +91 +0.4%
TAM
32
Tocqueville Asset Management
New York
$324K -$50.5K -3,500 -16%
HCM
33
Highbridge Capital Management
New York
$314K +$265K +18,408 New
HVC
34
Healthcare Value Capital
New Jersey
$281K – – –
TA
35
Teachers Advisors
New York
$281K – – –
PPA
36
Parametric Portfolio Associates
Washington
$276K +$233K +16,150 New
CD
37
Carl Domino
Florida
$252K -$107K -7,400 -33%
Charles Schwab
38
Charles Schwab
California
$222K – – –
Canada Life
39
Canada Life
Manitoba, Canada
$220K +$186K +12,900 New
ORI
40
Oak Ridge Investments
Illinois
$218K -$18.1K -1,257 -9%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$210K -$98.3K -6,815 -36%
CIA
42
Capital Impact Advisors
Massachusetts
$173K – – –
ERIM
43
Eagle Ridge Investment Management
Connecticut
$171K +$144K +10,000 New
Morgan Stanley
44
Morgan Stanley
New York
$156K +$43.8K +3,034 +50%
NFA
45
Nationwide Fund Advisors
Ohio
$153K – – –
AIG
46
American International Group
New York
$124K -$4.15K -288 -4%
Citigroup
47
Citigroup
New York
$107K +$21K +1,456 +31%
Deutsche Bank
48
Deutsche Bank
Germany
$98K +$53.5K +3,712 +177%
BA
49
BlackRock Advisors
Delaware
$96K -$212K -14,672 -72%
UBS Group
50
UBS Group
Switzerland
$57K +$48.3K +3,350 New
1
2
3

STML Hedge Fund Activity: Q4 2014 in Review

62 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2014, worth a combined $130M — up 46% from $88.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new STML positions and 8 closed out — a net gain of 3 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was VHCP Management, adding an estimated $4.12M. The largest seller was Artal Group, exiting entirely with an estimated $2.12M sold.

  • 62 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2014, up from 61 in Q3 2014.
  • Funds reported $130M of Stemline Therapeutics, Inc. stock for Q4 2014, up 46% quarter-over-quarter.
  • 11 funds opened new Stemline Therapeutics, Inc. positions in Q4 2014 and 8 closed out, a net change of +3 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q4 2014 was VHCP Management, an estimated $4.12M added.
  • The largest Stemline Therapeutics, Inc. seller in Q4 2014 was Artal Group, an estimated $2.12M sold.

Based on aggregated 13F filings for Q4 2014.